Synthetic Biologics(TOVX) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results Target patient enrollment of 92 evaluable patients achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metastatic pancreatic ductal adenocarcinoma Manufacturing funding awarded by the Spanish Government's National Knowledge Transfer Program Data and Safety Monitoring Committee Review of Phase 1b/2a SYN-004 in allogeneic hematopoietic cell transplant recipients recommends expansion to ...